SCHEMBL1067345

SCHEMBL1067345

CCOC(=O)C=C(CBr)Oc1cc(C)ccc1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.36
CYP4A11 Q02928 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 5/20 0.34
MAPT P10636 4/20 0.34
RAB9A P51151 3/20 0.34
PKM P14618 2/20 0.34
NPC1 O15118 1/20 0.34
NPSR1 Q6W5P4 3/20 0.33
POLB P06746 2/20 0.33
CYP3A4 P08684 1/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 3/20 0.32
HPGD P15428 2/20 0.32
LMNA P02545 2/20 0.32
TP53 P04637 1/20 0.32
MAOB P27338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1067344 1.00 CYP4F2 (0.36) CYP4F2CYP4A11CYP1A2CYP2C9CYP2C19
SCHEMBL1067343 1.00 CYP4F2 (0.36) CYP4F2CYP4A11CYP1A2CYP2C9CYP2C19
SCHEMBL1067438 0.90 MAPT (0.38) CYP4F2CYP4A11CYP1A2CYP2C9CYP2C19
SCHEMBL1067440 0.90 MAPT (0.38) CYP4F2CYP4A11CYP1A2CYP2C9CYP2C19
SCHEMBL1067242 0.84 NPSR1 (0.35) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPT
SCHEMBL1068355 0.84 FAAH (0.39) CYP1A2CYP2C19SMN1; SMN2MAPTRAB9A
SCHEMBL1068354 0.84 FAAH (0.39) CYP1A2CYP2C19SMN1; SMN2MAPTRAB9A
SCHEMBL1066851 0.83 CYP4F2 (0.41) CYP4F2CYP4A11CYP1A2CYP2C9CYP2C19
SCHEMBL1066854 0.83 CYP4F2 (0.41) CYP4F2CYP4A11CYP1A2CYP2C9CYP2C19
SCHEMBL1067369 0.82 TSHR (0.42) CYP1A2CYP2C9CYP2C19MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 CYP4F2 1365/4885CYP4A11 2671/4885CYP1A2 1710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.